fbpx

EssilorLuxottica and Dolce&Gabbana Announce 16-year Licensing Renewal

EssilorLuxottica and Dolce&Gabbana announce the early renewal of their licensing agreement for the development, production and worldwide distribution of prescription frames and sunglasses under the Dolce&Gabbana brand.

The existing agreement, which took effect on January 1, 2020, and was scheduled to expire on December 31, 2029, has been renewed and replaced with a new accord, lasting 16 years, effective January 1, 2024 until December 31, 2039.

The renewal, ahead of its natural expiration, and its duration are testament to the strong confidence and collaboration between the two companies since 2005.

Dolce&Gabbana has held a special place in our hearts over two decades. Since our stories intertwined, we have created some beautiful, memorable and innovative frames together, each a ‘made in Italy’ masterpiece. We have cultivated a love, admiration and loyalty among the most discerning consumers, developing a deep trust and respect for each other along the way. Our early renewal signals the strong bond between our companies and the promise that luxury eyewear represents in the decades ahead.”

Francesco Milleri, Chairman and CEO at EssilorLuxottica

“EssilorLuxottica and Dolce&Gabbana have built a powerfully effective partnership over the last 19 years, both in business and creativity. Today’s long-term renewal is representative of our shared confidence in the future opportunities from which both parties will benefit as we continue to work together in the years ahead. EssilorLuxottica’s unparalleled know-how in the manufacture of eyewear is matched only by the scale and quality of its global network of retail and distribution. Dolce&Gabbana is delighted to confirm today’s renewal.”

Alfonso Dolce, CEO at Dolce&Gabbana

Click HERE for the full press release.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!

Featured Posts

Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read More
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read More
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read More
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read More
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more
Fighting Blindness Canada

Clinical Trial Results for New Treatments for AMD and DME

Anti-VEGF medications can prevent vision loss and even restore some vision for age-related macular degeneration (AMD) patients. However, they require frequent eye injections which cause anxiety and side effects.

Learn More
Centre for Ocular Research & Education (CORE)

LVPEI and CORE Sign Partnership Agreement for Vision Science and Therapeutic Development

L.V. Prasad Eye Institute (LVPEI) and the Centre for Ocular Research & Education (CORE) at the University of Waterloo have entered into a strategic partnership to advance vision science research and therapeutic development, as well as to enhance eye care delivery on a global scale.

Read more
Silhouette Titan Minimal Art Sun

Celebrating 25 Years of Frameless Elegance and UV Protection

Silhouette’s Titan Minimal Art Sun launches new sunglass models: ADARA, CALEUM (featured model) and GLENN featuring hyper-flexing temples and premium materials.

Read more
The Vision Council logo

The Vision Council Supports National Eye Institute in Celebrating Healthy Vision Month

This Year’s Campaign Shines a Light on Vision Loss and its Impact on Mental Health

Read more
VTI NaturalVue

New Data from VTI’s PROTECT Clinical Trial for Myopia Progression Control Presented at ARVO

Visioneering Technologies, Inc, producer of the NaturalVue® Multifocal 1 Day Contact Lenses (NVMF), continued its release of the 1-year prospective data of its ongoing multi-center, randomized, double-masked, controlled trial (RCT) at the Association for Research in Vision and Ophthalmology (ARVO).

Read more